ENTRESTO simultaneously enhances the beneficial vasculatory effects of the natriuretic peptide system whilst inhibiting the detrimental effects of the renin–angiotensin–aldosterone system.1
Vardeny O, et al. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure CME. J Am Coll Cardiol Heart Fail 2014;2(6):663–670.
Date of preparation: July 2016 ENT16-C022c(1)
Novartis Pharmaceuticals UK Ltd assumes no responsibility for the site or its content.